QUETIAPINE MARKET

INTRODUCTION

Quetiapine is an atypical antipsychotic drug used to treat major depressive disorder, bipolar disorder, and schizophrenia. Because to its sedative effect, it is frequently used as a sleep aid, however the advantages of doing so do not always seem to outweigh the drawbacks. It's consumed orally. Constipation, weight gain, drowsiness, and dry mouth are typical adverse effects.

A prolonged erection, seizures, excessive blood sugar, tardive dyskinesia, and neuroleptic malignant syndrome are a few other side effects. Its use raises the chance of death in elderly dementia patients. Usage during the third trimester of pregnancy may cause the infant to have a mobility issue for a while after birth.

Serotonin and dopamine receptors are only a couple of the receptors quetiapine is thought to disrupt in order to act. However, due to the high incidence of attrition in trials and the absence of information on economic consequences, social functioning, or quality of life, clear conclusions are not feasible.

There is questionable evidence that quetiapine is superior to placebo in treating schizophrenia. The effectiveness of conventional and atypical antipsychotics as a class is up for debate. When topicals are used at low to moderate dosages, both have equal drop-out and symptom recurrence rates.

Quetiapine causes more dry mouth and tiredness than other drugs, although having lower incidence of extrapyramidal adverse effects.

quetiapine to other atypical antipsychotic agents tentatively concluded that it may be less efficacious than olanzapine and risperidone; produce fewer movement related side effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine; and produce weight gain similar to risperidone, clozapine and aripiprazole.

They came to the conclusion that it had similar side effects to first-generation antipsychotics in terms of suicide attempt, suicide, and mortality as well as QTc prolongation, low blood pressure, tachycardia, drowsiness, gynecomastia, galactorrhea, monthly irregularity, and white blood cell count.

QUETIAPINE MARKET SIZE AND FORECAST

 The Global Quetiapine Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

QUETIAPINE MARKET NEW PRODUCT LAUNCH

After the US Food & Drug Administration's clearance of Dr. Reddy's ANDA for Quetiapine fumarate tablets, Dr. Reddy's Laboratories stated that it has launched Quetiapine fumarate tablets, a bioequivalent generic form of SEROQUEL tablets.

100 and 500 count bottles of Dr. Reddy's Quetiapine fumarate tablets in the dosages of 25 mg and 50 mg, 100 mg, 200 mg, and 400 mg, and 60 count bottles of the 300 mg dosage are also available. 

QUETIAPINE MARKET COMPANY PROFILE

•  Dr. Reddy's Laboratories
• Suafarma
•  Menadiona
•  S.L.
•  Vasudha Pharma Chem Ltd.
• DKSH
•  Otto

THIS QUETIAPINE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Quetiapine  are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Quetiapine  and key vendor selection criteria
3. Where is the Quetiapine  manufactured? What is the average margin per unit?
4. Market share of Global Quetiapine  market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Quetiapine  in-house
6. key predictions for next 5 years in Global Quetiapine  market
7. Average B-2-B Quetiapine  market price in all segments
8. Latest trends in Quetiapine  market, by every market segment
9. The market size (both volume and value) of the Quetiapine  market in 2024-2030 and every year in between?
10. Production breakup of Quetiapine  market, by suppliers and their OEM relationship